11 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
| FY | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| 2025 | $236M | -$40M | 73.1% | -16.6% | -$16M | $106M | $20M |
| 2024 | $205M | -$38M | 72.6% | -17.1% | -$41M | $77M | $44M |
| 2023 | $149M | -$21M | 74.8% | -18.0% | -$44M | $11M | $31M |
| 2022 | $122M | $1M | 74.1% | -20.8% | -$32M | $907000 | $9M |
| 2021 | $98M | -$16M | 74.9% | -18.4% | -$21M | $1M | $8M |
| 2020 | $71M | -$33M | 77.4% | -37.6% | -$29M | $1M | $29M |
| 2019 | $73M | -$14M | 75.3% | -12.5% | -$30M | $26M | $71M |
| 2018 | $58M | -$12M | 74.2% | -16.6% | -$21M | $21M | $61M |
| 2017 | $46M | -$9M | 75.5% | -14.2% | -$12M | $25M | $43M |
| 2016 | $37M | -$7M | 70.7% | -16.4% | -$5M | $18M | $2M |
| 2015 | — | -$8M | — | — | -$3M | — | $4M |
| Quarter | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| Mar '26 | $59M | -$11M | 73.1% | -14.0% | -$5M | $107M | $12M |
| Dec '25 | $62M | -$10M | 73.2% | -13.3% | $10M | $106M | $20M |
| Sep '25 | $61M | -$12M | 73.9% | -15.4% | -$3M | $105M | $17M |
| Jun '25 | $61M | -$7M | 72.1% | -17.4% | -$14M | $103M | $45M |
| Mar '25 | $52M | -$11M | 73.0% | -21.0% | -$8M | $77M | $33M |
| Dec '24 | $53M | -$16M | 67.5% | -26.7% | -$4M | $77M | $44M |
| Sep '24 | $55M | -$8M | 73.4% | -10.2% | -$12M | $77M | $51M |
| Jun '24 | $53M | -$6M | 77.3% | -10.7% | -$13M | $11M | $29M |
| Mar '24 | $45M | -$8M | 72.0% | -21.8% | -$13M | $11M | $22M |
| Dec '23 | $38M | -$7M | 71.0% | -21.4% | -$11M | $11M | $31M |
| Sep '23 | $40M | -$5M | 77.4% | -11.3% | -$11M | — | $11M |
| Jun '23 | $40M | -$3M | 75.9% | -14.1% | -$10M | — | $10M |
| Mar '23 | $32M | -$7M | 74.6% | -27.2% | -$11M | — | $35M |
| Dec '22 | $31M | -$8M | 68.5% | -26.8% | -$3M | $907000 | $9M |
| Sep '22 | $35M | $19M | 74.1% | -19.9% | -$7M | — | — |
| Jun '22 | $33M | -$333000 | 75.9% | -11.4% | -$13M | $32M | $37M |
| Mar '22 | $23M | -$9M | 79.3% | -27.3% | -$8M | — | $18M |
| Dec '21 | $25M | $72000 | 72.9% | -22.4% | -$3M | $1M | $8M |
| Sep '21 | $25M | -$2M | 74.0% | -14.5% | -$3M | — | $6M |
| Jun '21 | $27M | -$4M | 76.6% | -10.7% | -$11M | — | $11M |
How the market has priced KIDS against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
Over the past 5 years, ORTHOPEDIATRICS CORP's revenue has grown 27.2% per year. These are computed facts, not advice.
As of FY2025, ORTHOPEDIATRICS CORP reported $106M of total debt against $20M of cash; operating income covered interest expense -6.5×.
In FY2025, gross margin was 73.1%, operating margin -16.6%, and net margin -16.8%.
As of Jun '26, ORTHOPEDIATRICS CORP traded at a price-to-earnings ratio of about 664.2× (market cap ÷ latest annual net income). The valuation charts above show how its P/E, P/S have moved with the share price. These are computed facts, not advice.
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.